Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. (2022)
Attributed to:
Evidence synthesis of diagnostic test performance from a decision-making perspective
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/neuonc/noab247
PubMed Identifier: 34718782
Publication URI: http://europepmc.org/abstract/MED/34718782
Type: Journal Article/Review
Volume: 24
Parent Publication: Neuro-oncology
Issue: 4
ISSN: 1522-8517